The majority of breast tumors express the estrogen receptor-α (ERα) that plays important roles in breast cancer pathogenesis and progression, and hormonal therapies such as tamoxifen (TAM) are the first line of adjuvant therapy.1, 2 Unfortunately, 30% of these patients will ultimately fail therapy because of de novo or acquired resistance. Here, ESR1 is linked to breast carcinoma.